Bicycle Therapeutics (BCYC) EBIT (2018 - 2026)

Bicycle Therapeutics has reported EBIT for 9 years, with the latest figure at -$65.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 6.73% year-over-year to -$65.5 million; the trailing twelve-month figure through Mar 2026 stood at -$242.3 million (up 2.42% YoY), and the FY2025 full-year result was -$247.1 million, down 17.72% from the prior year.
• EBIT for Q1 2026 stood at -$65.5 million, down from -$24.7 million in the prior quarter.
• The five-year high for EBIT was -$24.7 million in Q4 2025, with the low at -$86.6 million in Q2 2025.
• Historically, EBIT has averaged -$48.8 million across 5 years, with a median of -$46.6 million in 2024.
• The largest YoY upside for EBIT was 63.48% in 2025 against a maximum downside of 121.35% in 2025.
• Bicycle Therapeutics' EBIT stood at -$32.2 million in 2022, then tumbled by 68.37% to -$54.2 million in 2023, then retreated by 24.76% to -$67.7 million in 2024, then surged by 63.48% to -$24.7 million in 2025, then plunged by 165.02% to -$65.5 million in 2026.
• The last three EBIT figures came in at -$65.5 million (Q1 2026), -$24.7 million (Q4 2025), and -$65.6 million (Q3 2025), per Business Quant data.